SCHOTT Pharma AG & Co. KGaA

DB:1SXP Stock Report

Market Cap: €4.4b

SCHOTT Pharma KGaA Valuation

Is 1SXP undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 1SXP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 1SXP (€29.78) is trading below our estimate of fair value (€31.26)

Significantly Below Fair Value: 1SXP is trading below fair value, but not by a significant amount.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1SXP?

Other financial metrics that can be useful for relative valuation.

1SXP key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue4.9x
Enterprise Value/EBITDA18.9x
PEG Ratio1.9x

Price to Earnings Ratio vs Peers

How does 1SXP's PE Ratio compare to its peers?

The above table shows the PE ratio for 1SXP vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average22.5x
GXI Gerresheimer
22x22.8%€2.6b
DMP Dermapharm Holding
21.7x20.0%€1.8b
BIO3 Biotest
6.7x-67.2%€1.4b
STVN Stevanato Group
39.7x18.1%US$5.5b
1SXP SCHOTT Pharma KGaA
29.4x15.9%€4.4b

Price-To-Earnings vs Peers: 1SXP is expensive based on its Price-To-Earnings Ratio (29.4x) compared to the peer average (22.5x).


Price to Earnings Ratio vs Industry

How does 1SXP's PE Ratio compare vs other companies in the European Life Sciences Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a25.9%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a25.9%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: 1SXP is good value based on its Price-To-Earnings Ratio (29.4x) compared to the European Life Sciences industry average (46.4x).


Price to Earnings Ratio vs Fair Ratio

What is 1SXP's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1SXP PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio29.4x
Fair PE Ratio19.7x

Price-To-Earnings vs Fair Ratio: 1SXP is expensive based on its Price-To-Earnings Ratio (29.4x) compared to the estimated Fair Price-To-Earnings Ratio (19.7x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 1SXP forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€29.78
€34.76
+16.7%
7.4%€39.00€31.80n/a11
Sep ’25€35.64
€34.49
-3.2%
11.3%€44.00€30.00n/a11
Aug ’25€31.76
€34.21
+7.7%
11.4%€44.00€30.00n/a11
Jul ’25€31.42
€34.03
+8.3%
11.2%€44.00€30.00n/a11
Jun ’25€29.28
€34.84
+19.0%
13.6%€44.00€25.00n/a11
May ’25€40.10
€38.67
-3.6%
12.5%€45.00€30.00n/a10
Apr ’25€39.20
€38.31
-2.3%
13.6%€45.00€30.00n/a9
Mar ’25€39.00
€37.98
-2.6%
13.5%€45.00€30.00n/a8
Feb ’25€36.60
€33.54
-8.4%
8.2%€38.00€30.00n/a8
Jan ’25€33.80
€32.30
-4.4%
9.2%€37.00€27.50n/a8
Dec ’24€29.40
€31.91
+8.6%
7.0%€34.00€27.50n/a7

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies